Page 37 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Role of common CXC chemokines in NAFLD

doi: 10.2741/2853 52. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8
and its receptors in gliomagenesis and tumoral angiogenesis.
41. Haskill S, Peace A, Morris J, et al. Identification of three
related human GRO genes encoding cytokine functions. Neuro Oncol. 2005;7(2):122-133.
Proc Natl Acad Sci U S A. 1990;87(19):7732-7736. doi: 10.1215/S1152851704001061
doi: 10.1073/pnas.87.19.7732 53. Stephens M, Von Der Weid PY. Lipopolysaccharides modulate
42. Burke SJ, Lu D, Sparer TE, et al. NF-ΚB and STAT1 control intestinal epithelial permeability and inflammation in a
CXCL1 and CXCL2 gene transcription. Am J Physiol species-specific manner. Gut Microbes. 2020;11(3):421-432.
Endocrinol Metab. 2014;306(2):E131-E149. doi: 10.1080/19490976.2019.1629235
doi: 10.1152/ajpendo.00347.2013 54. Zhu Y, Yang S, Zhao N, et al. CXCL8 chemokine in ulcerative
43. Kim DS, Han JH, Kwon HJ. NF-Kappab and c-jun- colitis. Biomed Pharmacother. 2021;138:111427.
dependent regulation of macrophage inflammatory doi: 10.1016/j.biopha.2021.111427
protein-2 gene expression in response to lipopolysaccharide
in RAW 264.7 cells. Mol Immunol. 2003;40(9):633-643. 55. McHenry S, Glover M, Ahmed A, et al. NAFLD is associated
with quiescent rather than active Crohn’s disease. Inflamm
doi: 10.1016/j.molimm.2003.07.001 Bowel Dis. 2023;30(5):757-767.
44. Pan X, Chiwanda Kaminga A, Liu A, Wen SW, Chen J, doi: 10.1093/ibd/izad129
Luo J. Chemokines in non-alcoholic fatty liver disease:
A systematic review and network meta-analysis. Front 56. Li XP, Yang XY, Biskup E, et al. Co-expression of CXCL8
Immunol. 2020;11:1802. and HIF-1α is associated with metastasis and poor
prognosis in hepatocellular carcinoma. Oncotarget.
doi: 10.3389/fimmu.2020.01802
2015;6(26):22880-22889.
45. Sanchez JI, Parra ER, Jiao J, et al. Cellular and molecular doi: 10.18632/oncotarget.4412
mechanisms of liver fibrosis in patients with NAFLD.
Cancers (Basel). 2023;15(11):2871. 57. Stienstra R, Saudale F, Duval C, et al. Kupffer cells
promote hepatic steatosis via interleukin-1beta-dependent
doi: 10.3390/cancers15112871
suppression of peroxisome proliferator-activated receptor
46. Han YH, Choi H, Kim HJ, Lee MO. Chemotactic cytokines alpha activity. Hepatology. 2010;51(2):511-522.
secreted from kupffer cells contribute to the sex-dependent doi: 10.1002/hep.23337
susceptibility to non-alcoholic fatty liver diseases in mice.
Life Sci. 2022;306:120846. 58. Auguet T, Bertran L, Binetti J, et al. Relationship between IL-8
circulating levels and TLR2 hepatic expression in women
doi: 10.1016/j.lfs.2022.120846
with morbid obesity and nonalcoholic steatohepatitis. Int J
47. Barreyro FJ, Holod S, Finocchietto PV, et al. The pan-caspase Mol Sci. 2020;21(11):4189.
inhibitor emricasan (IDN-6556) decreases liver injury and
fibrosis in a murine model of non-alcoholic steatohepatitis. doi: 10.3390/ijms21114189
Liver Int. 2015;35(3):953-966. 59. Stratakis N, Golden-Mason L, Margetaki K, et al. In
doi: 10.1111/liv.12570 utero exposure to mercury is associated with increased
susceptibility to liver injury and inflammation in childhood.
48. Morán-Salvador E, Titos E, Rius B, et al. Cell-specific PPARγ Hepatology. 2021;74(3):1546-1559.
deficiency establishes anti-inflammatory and anti-fibrogenic
properties for this nuclear receptor in non-parenchymal doi: 10.1002/hep.31809
liver cells. J Hepatol. 2013;59(5):1045-1053. 60. Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10,
doi: 10.1016/j.jhep.2013.06.023 CXCL11/CXCR3 axis for immune activation-A target for
novel cancer therapy. Cancer Treat Rev. 2018;63:40-47.
49. Zhang X, Fan L, Wu J, et al. Macrophage p38α promotes
nutritional steatohepatitis through M1 polarization. doi: 10.1016/j.ctrv.2017.11.007
J Hepatol. 2019;71(1):163-174. 61. Rotondi M, Chiovato L, Romagnani S, Serio M,
doi: 10.1016/j.jhep.2019.03.014 Romagnani P. Role of chemokines in endocrine autoimmune
diseases. Endocr Rev. 2007;28(5):492-520.
50. Waugh DJJ, Wilson C. The interleukin-8 pathway in cancer.
Clin Cancer Res. 2008;14(21):6735-6741. doi: 10.1210/er.2006-0044
doi: 10.1158/1078-0432.CCR-07-4843 62. Zhang X, Shen J, Man K, et al. CXCL10 plays a key role as an
inflammatory mediator and a non-invasive biomarker of non-
51. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M.
Multiple control of interleukin-8 gene expression. J Leukoc alcoholic steatohepatitis. J Hepatol. 2014;61(6):1365-1375.
Biol. 2002;72(5):847-855. doi: 10.1016/j.jhep.2014.07.006

Volume 9 Issue 3 (2025) 29 doi: 10.36922/ejmo.8383